Skip to search boxSkip to navigationSkip to main content

Evolution of COVID-19 seroprevalence in blood banks during the pandemic in the Lima region, Peru

Original title: Evolución de la seroprevalencia de COVID-19 en bancos de sangre durante la pandemia en la región Lima, Perú
  • Teófilo José Fuentes Rivera
    ,
  • Juan Antonio Almeyda Alcántara
    ,
  • Alex Nader Celada Padilla(corresponding author)
    ,
  • Rosemary Sunilda Fernández Fuentes
    ,
  • Liliana Estefania Nicho Machado
    ,
  • Luis Palma Garcia
*Corresponding author for this work
  • Trasplantes y Banco de Sangre
    ,
  • Hospital Emergencia Ate Vitarte
    ,
  • Hospital Nacional Hipólito Unanue
    ,
  • Hospital Nacional Arzobispo Loayza
    ,
  • Hospital General de Huacho
    ,
  • Hospital Nacional Sergio Enrique Bemales
Research Output:
Contribution to journal
Article
Research
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Research
Peer-review

Original language

Spanish

Pages from-to (Number of pages)

Pages 124-130 (7 pages)

Journal (Volume, Issue Number)

Anales de la Facultad de Medicina (Volume 85, Issue 2)

Publication milestones

  • Published - 2024

Publication status

Published - 2024

ISSN

1025-5583

Publication IDs

  • Scopus: 85204453879

Abstract

Introduction. Peru was one of the countries most affected by the COVID-19 pandemic, with more than 220,000 deaths recorded due to SARS-CoV-2 infection. Given the constant mutations of the virus and registered variants, it is important to carry out research that reflects the evolution of the humoral immune state. Objective. Measure the seroprevalence of COVID-19 during the pandemic in the department of Lima in the period between April 1, 2020 and June 30, 2022, in donor samples from 6 hospital blood banks public of Lima, Peru. Methods. A descriptive, transversal, observational and retrospective study was carried out evaluating the presence of IgM/IgG antibodies against SARS-CoV-2 using lateral flow chromatographic immunoassay in samples from healthy and asymptomatic donors from blood banks of 6 health facilities in the department of Lima. Results. A progressive increase in the seroprevalence of IgG and total reactivity of IgM/IgG antibodies against SARS-CoV-2 will be observed as follows: 22,6% - 32,7% during 2020; 53,9% - 58,1% during 2021; 88,9% - 93,3% during the first half of 2022. Conclusions. The reactivity and presence of anti-SARS-CoV-2 antibodies progressively increase during the COVID-19 pandemic from 11,2% to 98,4% in the samples evaluated, possibly with the impact of the pandemic waves and the active vaccination campaign against COVID-19.

Publication metrics

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well